Chemerin Elicits Potent Constrictor Actions via Chemokine-Like Receptor 1 (CMKLR1), not G-Protein-Coupled Receptor 1 (GPR1), in Human and Rat Vasculature by Kennedy, AJ et al.
Chemerin Elicits Potent Constrictor Actions via Chemokine-Like
Receptor 1 (CMKLR1), not G-Protein-Coupled Receptor 1 (GPR1),
in Human and Rat Vasculature
Amanda J. Kennedy, MChem; Peiran Yang, MRes; Cai Read, MRes; Rhoda E. Kuc, GiBiol; Lucy Yang, MBChB, MPhil; Emily J. A. Taylor, PhD;
Colin W. Taylor, PhD; Janet J. Maguire, PhD; Anthony P. Davenport, PhD
Background-—Circulating levels of chemerin are signiﬁcantly higher in hypertensive patients and positively correlate with blood
pressure. Chemerin activates chemokine-like receptor 1 (CMKLR1 or ChemR23) and is proposed to activate the “orphan” G-
protein-coupled receptor 1 (GPR1), which has been linked with hypertension. Our aim was to localize chemerin, CMKLR1, and
GPR1 in the human vasculature and determine whether 1 or both of these receptors mediate vasoconstriction.
Methods and Results-—Using immunohistochemistry and molecular biology in conduit arteries and veins and resistance vessels,
we localized chemerin to endothelium, smooth muscle, and adventitia and found that CMKLR1 and GPR1 were widely expressed in
smooth muscle. C9 (chemerin149–157) contracted human saphenous vein (pD2=7.300.31) and resistance arteries
(pD2=7.050.54) and increased blood pressure in rats by 9.11.0 mm Hg at 200 nmol. Crucially, these in vitro and in vivo
vascular actions were blocked by CCX832, which we conﬁrmed to be highly selective for CMKLR1 over GPR1. C9 inhibited cAMP
accumulation in human aortic smooth muscle cells and preconstricted rat aorta, consistent with the observed vasoconstrictor
action. Downstream signaling was explored further and, compared to chemerin, C9 showed a bias factor=5000 for the Gi protein
pathway, suggesting that CMKLR1 exhibits biased agonism.
Conclusions-—Our data suggest that chemerin acts at CMKLR1, but not GPR1, to increase blood pressure. Chemerin has an
established detrimental role in metabolic syndrome, and these direct vascular actions may contribute to hypertension, an
additional risk factor for cardiovascular disease. This study provides proof of principle for the therapeutic potential of selective
CMKLR1 antagonists. ( J Am Heart Assoc. 2016;5:e004421 doi: 10.1161/JAHA.116.004421)
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C hemerin is a 16-kDa protein that has been identiﬁed as achemokine and adipokine with well-established roles in
inﬂammation and obesity.1 Recently, it has been reported to
have a number of physiological and pathophysiological
actions, suggesting a potential new role in the cardiovascular
system.2 Chemerin enables chemotaxis of dendritic cells and
macrophages to sites of injury,3,4 alters plasma lipid and
glucose levels,5 and promotes angiogenesis.6 Hypertensive
patients have signiﬁcantly higher plasma concentrations of
chemerin compared to healthy controls, and levels of
chemerin positively correlate with body mass index (BMI),
systolic and diastolic blood pressure, triglycerides, and fasting
plasma glucose and insulin concentrations.7,8
Chemerin was thought to mediate its actions through a
single G-protein-coupled receptor (GPCR) encoded by the
chemokine-like receptor 1 (CMKLR1) gene (also known as
ChemR23).6,9–12 However, recently, chemerin has been
proposed to bind and activate a second GPCR, GPR1,13
which has a 37% sequence identity with CMKLR1. GPR1 is
currently classiﬁed as an “orphan,” although this possible
pairing with chemerin has been independently conﬁrmed.14–16
GPR1 was mapped to a region of interest in the British
Genetics of Hypertension (BRIGHT) study,17 implicating it as a
candidate in control of blood pressure.
To date, the actions of chemerin on vascular reactivity in
humans has not been extensively studied, and a consistent
pattern has not emerged from the limited studies carried out in
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animal models. Given that chemerin is a large protein, it is
preferable to identify tool compounds to characterize its
function in vitro and in vivo. Other agonists, such as the
C-terminal fragment, C9 (chemerin149–157), have been
identiﬁed and are reported to mimic the actions of full-length
chemerin.18 Watts et al19 found that whereas C9 caused a
concentration-dependent contraction in a rat conduit vessel
(aorta) in vitro through CMKLR1, they reported no action in vivo
in this species. These researchers also found no response to
chemerin in mouse aorta, whereas Kunimoto et al20 reported
that chronic infusion of C9 caused an increase in systolic blood
pressure in mice in vivo, but did not identify the receptor
mediating this effect. Therefore, data from these rodent
studies are currently conﬂicting and require clariﬁcation.
GPCRs include many of the most successfully exploited
drug targets. At present, hypertension and associated
pathologies remain an unresolved clinical problem, and
current therapies are not cures. The chemerin signaling
pathway may therefore be an additional target for transla-
tional research. We hypothesize that chemerin has signiﬁcant
vascular effects, in humans, mediated by 1 or both of the
receptors, CMKLR1 and GPR1. In this study, we show that
CMKLR1 and GPR1 are widely expressed in smooth muscle of
the human vasculature. We have fully characterized a small-
molecule selective antagonist of CMKLR1 and provide com-
pelling evidence that, in the human vasculature and rats
in vivo, CMKLR1 mediates the vasoconstrictor actions of C9.
We believe our data will advance the ﬁeld by identifying that




Human recombinant chemerin(21–157) was purchased from
R&D Systems Incorporated (Minneapolis, MN). Human C9,
chemerin(149–157), was synthesised by Eurogentec (Liege,
Belgium) or purchased from AnaSpec (Fremont, CA). Human C9
from AnaSpec was custom iodinated on the N-terminal tyrosine
residue ([Tyr149][125I]C9) by Anawa (Wangan, Switzerland).
Human C13, chemerin(145–157), was from Phoenix Pharma-
ceuticals (Belmont, CA). CCX832 was kindly gifted by Dr Matt
Barnes (Takeda, Cambridge, UK). All other reagents were from
Sigma-Aldrich Ltd (Poole, UK), unless otherwise stated.
Human Tissue
Human tissues were obtained with informed consent from the
Papworth Hospital Research Tissue Bank (REC reference 08/
H0304/56). Experimental work was carried out with local
ethical approval (REC 05/Q0104/142) and conformed to the
principles outlined in the Declaration of Helsinki. Saphenous
vein (SV) and mammary artery (MA) were from patients
receiving coronary artery bypass grafts. Coronary artery (CA),
left ventricle (LV), aorta (AO), and lung were from patients
undergoing cardiac transplantation. Kidney tissue was from
patients undergoing nephrectomy for nonobstructive carci-
noma. Small subcutaneous resistance arteries were obtained
from unused abdominal tissue and collected from patients
undergoing abdominoplasty or breast reconstruction surgery.
Human aortic smooth muscle cells (ASMCs) were purchased
from American Tissue Culture Collection (Manassas, VA) (LGC
Standards). Cells were cultured according to the supplier’s
instructions.
Immunohistochemistry and Confocal Microscopy
Peroxidase/anti-peroxidase staining was conducted, as previ-
ously described,21 on frozen sections of human histologically
normal blood vessels, LV, lung, and kidney (all n=3) using
mouse anti-chemerin (1:300; ab72965; Abcam, Cambridge,
MA); rabbit anti-CMKLR1 (1:500; ab64881; Abcam), or rabbit
anti-GPR1 (1:300; ab150536; Abcam). To identify cellular
distribution, dual-labeling immunoﬂuorescent staining was
executed, as previously described,21 with frozen sections of
human histologically normal blood vessels (n=3) or human
ASMCs (n=3). Rabbit primary antiserum against human
CMKLR1 (1:100), GPR1 (1:50), or chemerin (1:25; ab103153;
Abcam) was applied together with either a mouse antihuman
von-Willebrand factor (vWF) antibody (1:50; Dako, Carpinteria,
CA), or mouse antihuman smooth muscle alpha actin (SmaA;
1:100; Dako). Secondary antibodies, Alexa Fluor 633 goat
antirabbit immunoglobulin G (IgG; 1:200) and Alexa Fluor 568
goat antimouse IgG (1:200; both from Life Technologies,
Carlsbad, CA) were used to avoid the autoﬂuorescence of
human vessels in the 488-nm channel.
All images were processed in Fiji,22,23 for background
subtraction, using the rolling ball method, histogram stretch-
ing, and merging of channels.
Quantitative Polmerase Chain Reaction
RNA extraction, using Trizol Reagent and the PureLink RNA
Mini Kit (Life Technologies) with DNase treatment, followed by
reverse transcription with the Promega Reverse Transcription
System (Promega, Madison, WI), were carried out, as in the
manufacturer’s instructions, on human SV (n=10), MA (n=8),
CA (n=5), aorta (n=5), and ASMCs (n=6), where n is the
number of different patients. cDNA products were puriﬁed
using the Wizard SV Gel and polymerase chain reaction (PCR)
Clean-Up System (Promega) and subjected to real-time
quantitative PCR for 45 cycles using the ABI 7500 Real-Time
PCR System (Life Technologies) with double-dye Taqman
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primer probes for human CMKLR1 (Hs01081979_s1), GPR1
(Hs00270990_s1), and RARRES2 (Hs00161209_g1) and
human 18S rRNA as an internal control, all from Life
Technologies. Expression of CMKLR1, GPR1, and RARRES2
(the gene for chemerin) was normalized to that of 18S.
Relative expression of CMKLR1, compared to GPR1, was
calculated using the DDCt (delta delta threshold cycle)
method and is expressed as fold-changeSEM, that is,
2(DDCt).24 Relative expression of RARRES2 in each tissue,
compared to expression in ASMCs, was calculated using the
DDCt method and is expressed as fold changeSEM, that is,
2(DDCt).
Radioligand Binding Assays
Experiments were conducted in assay buffer (50 nmol/L of
HEPES [pH 7.5], 1 mmol/L of CaCl2, 5 mmol/L of MgCl2, and
0.5% BSA), as previously described.25 Saturation binding was
carried out to determine the afﬁnity of [Tyr149][125I]C9 for
either human CMKLR1 or GPR1 heterologously expressed in
cells (n=3) or native receptors in human SV (n=3). Data were
analyzed using Equilibrium Binding Data Analysis and LIGAND
programs (KELL package; RADLIG, Cambridge, UK) to give
estimates of KD and Bmax values. In subsequent experiments,
homogenates were incubated with 0.1 nmol/L of [Tyr149]
[125I]C9 and C9 or CCX832 (0.01 nmol/L–1 lmol/L; n=3–6).
Data were analyzed to obtain the dissociation constant, pKi
(log10 dissociation constant), determined by the Cheng and
Prusoff equation using the half maximal inhibitory concentra-
tion values (concentration of unlabeled ligand required to
compete for 50% of the radiolabeled C9 binding) derived from
the competition curves using GraphPad Prism software
(version 6; GraphPad Software Inc., La Jolla, CA) (pKiSEM).
In Vitro Pharmacology of Human Vessels
To test the direct effect of chemerin on smooth muscle cells,
rings (4 mm) of human SV (n=6 patients) were rubbed on the
luminal surface to disrupt the endothelium and setup in organ
baths, as previously described.26 Endothelium-intact human
resistance arteries (2-mm rings; n=5 patients) were mounted in
wire myographs to investigate the actions of chemerin on
vessels physiologically relevant in blood pressure regulation.27
All experiments were carried out in modiﬁed Kreb’s solution
(89.2 mmol/L of NaCl; 29 mmol/L of NaHCO3; 5 mmol/L of
KCl; 0.49 mmol/L of MgSO4.7H2O and 1 mmol/L of Na2H-
PO4.2H2O, 2.25 mmol/L of CaCl2, 5 mmol/L of fumaric acid,
5 mmol/L of glutamic acid, 10 mmol/L of glucose, and
5 mmol/L of sodium pyruvate), and vessels were maintained
at 37°C with continuous oxygenation (95% O2/5% CO2).
Adjacent rings were treated with either CCX832 (100 nmol/
L) or vehicle (DMSO 0.001%), for 1 hour, before increasing
concentrations of C9 were added. Data were analyzed
(GraphPad Prism version 6; GraphPad Software Inc.) using the
4-parameter logistic curve, to give values of pD2 (-log10 EC50;
EC50 is the concentration producing half maximal response)
and Emax (maximum response), and antagonist afﬁnity, pA2
(logKB, where KB is the antagonist dissociation constant), was
determined using the Gaddum Schild equation. Agonist
responses were subsequently normalized to the maximum
response of C9 in the same tissue. All data are expressed as
meanSEM.
Effects of C9 and CCX832 in Vivo
Animal experiments were performed according to the local
ethics committee (University of Cambridge, Cambridge, CA)
and Home Ofﬁce guidelines under the 1986 Scientiﬁc
Procedures Act.
The surgical part of the experiment was performed as
previously described.28 Male Sprague-Dawley rats (2705 g)
were anesthetized (3% isoﬂurane to induce, 1.5% isoﬂurane to
maintain, inhaled), and level of anesthesia was monitored
using the toe pinch reﬂex, heart rate, and respiration rate. A
pressure volume catheter was inserted into the right carotid
artery. Compound additions were by intravenous injection
through the right jugular vein. Following baseline measure-
ments, rats received incremental doses to determine a 70%
effective concentration (EC70) of C9; in vivo, this dose (200-
nmol blous in 450 lL) was then used in all further studies.
Using the previously published data of Kunimoto et al,20
which showed a chemerin-induced increase in systolic blood
pressure, compared to control, in mice in vivo to derive effect
size d, a priori calculation using a=0.05 and power(1b)=0.8
to 0.9 computed the required sample size of n=6 to 8 in each
group (G*Power 3.1.9.2). We therefore stopped at 6 animals
in each group because of the size of the chemerin response
detected.
Rats (n=6 in each group) received 3 bolus doses (450 lL)
either: C9 (200 nmol), CCX832 (40 nmol), and C9 (200
nmol)+CCX832 (40 nmol), or in control rats C9 (200 nmol),
saline and C9 (200 nmol). The response to each injection was
monitored until returning to baseline or for at least 10 min-
utes. Rats were euthanized by exsanguination under high
isoﬂurane (5%) followed by cervical dislocation. Data analysis
was performed using LabChart 8, as previously described.29
Peak effects of C9 in the absence and presence of CCX832,
saline, and CCX832 on mean arterial blood pressure (MAP)
and heart rate (HR) are expressed as a change from baseline
and tested for signiﬁcance with a Student t test using using
GraphPad Prism software (version 6; GraphPad Software Inc.).
To determine the effect of CCX832 on C9 response, within
each rat, the second repeated dose of C9 in the absence and
presence of CCX832 was expressed as a percentage of the
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ﬁrst dose of C9 and tested for signiﬁcance with a Student t
test using using GraphPad Prism (version 6; GraphPad
Software Inc.).
Rat Aorta Contraction Assay
Rings (4 mm) of endothelium-denuded rat aorta (n=4 rats)
were set up in organ baths as described for human vessels,
and responses to increasing concentration of C9 were
measured. To investigate the role of cAMP in the constrictor
response, the following protocol was adapted from Alsaqati
et al.30 Vessels were preconstricted with U46619 (100 nmol/
L) and relaxed back to baseline with NKH477 (300 nmol/L),
which directly activates adenylyl cyclase, before responses to
C9 were measured. Responses are expressed as a percentage
of the maximum response to 100 mmol/L of KCl added at the
end of each experiment. Data were analyzed using a 4-
parameter logistic curve (GraphPad Prism 6; GraphPad Soft-
ware Inc.), to give values of pD2 and Emax. All data are
expressed as meanSEM.
cAMP Assays of Human ASMCs
Conﬂuent cultures of human ASMCs (n=3) labeled with [2,8-3H]
adenine (1 lCi/mL)were treatedwith CCX832 (100 nmol/L) or
vehicle (DMSO 0.001%) before addition of NKH477 (3 lmol/L)
in the absence or presence of C9 (1 lmol/L). Incubations were
terminated by aspirating the medium and addition of ice-cold
trichloroacetic acid (5% v/v). 3H-labeled adenine nucleotides
were separated as reported previously.31 Accumulation of 3H-
cAMP is expressed as a fraction of the sum of 3H-ATP, 3H-ADP,
and 3H-cAMP activities. Results with chemerin-related ligands
were then expressed as a percentage of the response evoked
by NHK477 alone and presented as meanSEM.
Cell-Based Functional Assays
b-Arrestin recruitment (CMKLR1 and GPR1) and cAMP assays
(CMKLR1; DiscoverX, Fremont, CA) were carried out with
CHO-K1 cells expressing either human CMKLR1 or GPR1,
according to the manufacturer’s instructions. In both assays,
Figure 1. Chemerin expression in human vessels: Representative photomicrographs show chemerin
(green) in smooth muscle cells (*) and endothelium (˄) of human (A) saphenous vein (SV), mammary artery
(MA), coronary artery (CA), and aorta (AO; all n=3 patients), with cell markers (red) smooth muscle alpha
actin (SMaA) or von Willebrand factor (vWF) and autoﬂuorescence in the 488-nm channel (in blue). L
denotes the lumen of the vessel and? expression in the adventitial layer of the MA. Scale bars=500 lm.
B, Expression of mRNA levels of chemerin in human vessels and ASMCs are shown relative to expression in
ASMCs and expressed as meanSEM (n=5–10 patients). ASMCs indicates aortic smooth muscle cells.
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agonist concentration-response curves, measured in relative
light units, were ﬁtted to a 4-parameter logistic concentration
response curve in GraphPad Prism software (version 6;
GraphPad Software Inc.), and values of pD2 and Emax were
calculated. Data were subsequently normalized to the max-
imum response to C13 used as the reference agonists in each
assay. For experiments with CCX832, antagonist afﬁnities,
pA2, were determined using the Gaddum Schild equation in
GraphPad Prism (version 6; GraphPad Software Inc.).
Analysis of C9 and C13 Signalling Pathway Bias
at CMKLR1
In cell-based assays (DiscoverX), where chemerin, C9, and
C13 were all tested in the same experiment, data were
analyzed as previously described32 to deﬁne the pathway
signaling proﬁle of C-terminal fragments C9 and C13
compared with chemerin and to quantify any bias for the
individual signaling pathways investigated.
Statistical Analysis
All results are reported as meanSEM. For human ASMC
studies in humans and in vivo animal studies, a 2-tailed
Student t test was used, as appropriate. Statistical signif-
icance was taken at the 5% level.
Results
Chemerin, CMKLR1, and GPR1 are Present in the
Human Cardiovascular System
mRNA encoding chemerin, CMKLR1, and GPR1 and the
corresponding proteins were widely expressed in human large
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Figure 2. Representative photomicrographs of human left ventricle (LV), lung, and kidney show: GPR1,
CMKLR1 and chemerin in human cardiomyocytes (A, B, and C, respectively); pulmonary vessels and
bronchioles (E, F, and G, respectively); renal tubular epithelial cells (I, J, and K, respectively); renal medulla
rays (M and N) and renal capillaries (O); and the corresponding no primary antibody controls (Q, R, and S).
Triangular arrows indicate endothelial lining, and asterisks indicate smooth muscle layer. Blue arrows
indicate bronchioles. Positive staining is shown as a brown product under the light microscope. H&E
staining was carried out on the same tissues (D, H, L, and P) with hematoxylin staining nuclei (blue) and
eosin staining protein structures (red). Scale bars=500 lm. CMKLR1 indicates chemokine-like receptor 1;
GPR1, G-protein-coupled receptor 1; H&E, hematoxylin and eosin.
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conduit arteries and veins and in resistance vessels. Chemerin
was present in the endothelium and smooth muscle medial
layer, as deﬁned by vWF and SMaA staining, respectively, of
histologically normal human SV, MA, AO, and CA, as well as
the adventitial layer of MA (Figure 1A). In sections of human
LV, lung, and kidney, chemerin was localized to endothelial
cells of small blood vessels and to endocardial endothelial
cells, epithelial cells of the lung bronchioles, and tubules and
Figure 3. CMKLR1 and GPR1 expression in human vessels: Representative photomicrographs show
CMKLR1 and GPR1 (green) in smooth muscle cells (*) and adventitia (?) of human (A) saphenous vein (SV),
mammary artery (MA), coronary artery (CA), and aorta (AO) and (B) ASMCs (all n=3 patients) with cell
marker (red) smooth muscle alpha actin (SMaA) and a corresponding no primary control, including
autoﬂuorescence, seen in the 488-nm channel. L denotes the lumen of the vessel. Cell nuclei stained with
4’,6-diamidino-2-phenylindole (blue). Scale bars=500 lm. C, Expression of mRNA for CMKLR1 (black) and
GPR1 (open bars) in human vessels and ASMCs are shown relative to expression of GPR1 and expressed as
meanSEM (n=5–10 patients). ASMCs indicates aortic smooth muscle cells; CMKLR1, chemokine-like
receptor 1; GPR1, G-protein-coupled receptor 1.
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endothelial cells in the kidney (Figure 2). Chemerin mRNA
levels were similar in human SV, MA, CA, and AO and less
abundant in ASMCs (Figure 1B).
CMKLR1 and GPR1 were detected in smooth muscle of
resistance vessels in human LV, lung, and kidney sections
and, additionally, to cardiomyocytes, bronchioles, and renal
tubules (Figure 2). CMKLR1 and GPR1 localized to the medial
layer of healthy human vessels (Figure 3A) and were
expressed in human ASMCs (Figure 3B). Both receptors were
also present in the adventitial layer of adipose tissue
surrounding human MA, CA, and AO (Figure 3A). Analysis of
mRNA for each receptor revealed that CMKLR1 was
expressed at higher levels than GPR1 in human vessels, but
there was relatively more GPR1 mRNA in human ASMCs
(Figure 3C).
Activation of CMKLR1 Caused Contraction of
Human Vessels
Radiolabeled binding studies with [Tyr149][125I]C9, in human SV
homogenate, revealed that C9 binds to a single site, with
a subnanomolar afﬁnity of KD=0.530.31 nmol/L and
Bmax=0.050.007 fmol/mg (Figure 4A). Unlabeled C9
(pKi=9.110.52) and reported CMKLR1 antagonist, CCX832
(pKi=8.650.38), compete for all the binding of radiolabeled
C9 (Figure 4B), suggesting that C9 is binding only to native
CMKLR1 receptors in human SV.
C9 caused a concentration-dependent contraction of
human SV (pD2=7.300.31). Preincubating the SV with
100 nmol/L of CCX832 before adding C9 caused a rightward
shift of the curve (pD2=6.570.62; Figure 4C and 4D) with a
pA2=8.390.15. Similarly, in the more physiologically
relevant human resistance arteries, C9 caused a concentra-
tion-dependent contraction (pD2=7.050.54), which was
antagonized when the vessel was pretreated with CCX832,
(pA2=7.960.34; Figure 4E). This study shows, for the ﬁrst
time, that activation of CMKLR1 causes contraction of human
blood vessels.
CMKLR1 Is a Novel Regulator of Blood Pressure
in Rats In Vivo
C9 caused a dose-dependent increase in MAP in rats
(Figure 5A), in vivo, with an EC70 of 200 nmol. C9 (200 nmol)
caused a signiﬁcant increase in MAP of 9.11.0 mm Hg
(Figure 5B). Repeated doses of C9 gave reproducible
increases in MAP (Figure 5C), with no evidence of
desensitization. CCX832 alone had no effect on MAP;
however, infusion of CCX832 with C9 caused a signiﬁcant
reduction in response compared to C9 alone (Figure 5D). C9
Figure 4. Binding and function of CMKLR1 in human tissues. Radiolabeled binding studies reveal that (A)
C9 binds to 1 site, with a subnanomolar afﬁnity (KD = 0.530.31 nmol/L; Bmax=0.050.007 fmol/mg;
n=3), and B, unlabeled C9 (▼, pKi=9.110.52; n=5) and CCX832 (■, pKi=8.650.38; n=6, pink) compete
for all the binding of radiolabeled C9 at native receptors. C9 induced a concentration-dependent
contraction of human vessels (blue), which was blocked by pretreatment with CCX832 (100 nmol/L, pink).
Raw trace of the response in SV (C) and the corresponding concentration-response curves to (▼) C9 and
(■) C9+100 nmol/L CCX832 in human SV (D; n=6 patients) and resistance arteries (E; (n=5 patients).
Responses are shown as % of maximal response to C9 and expressed as meanSEM. CMKLR1 indicates
chemokine-like receptor 1; SV, saphenous vein.
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and CCX832 had no effect on heart rate compared to
saline control (Figure 5E and 5F). Therefore, these data
identify CMKLR1 as a novel regulator of blood pressure
in vivo.
Chemerin Caused Vasoconstriction Through
Inhibition of cAMP Accumulation
In human ASMCs stimulated with NKH477 to directly activate
adenylyl cyclase, addition of C9 caused a signiﬁcant reduction
in the amount of cAMP accumulated. This inhibition of cAMP
accumulation by C9 was blocked by CCX832 (Figure 6A),
suggesting that C9 is modulating the response through
CMKLR1. In preconstricted rat aorta where NKH477 had
caused relaxation to the basal state, C9 induced more
contraction (pD2=6.420.17; Emax=14417% of that evoked
by KCl) than it did in na€ıve tissue (pD2=6.390.22;
Emax=6210%; Figure 6B). Consistent with a role in
contraction, these mechanistic studies show that activation
of CMKLR1 in the vasculature inhibits cAMP accumulation.
Conﬁrmation of the Pharmacology of C9 and
Antagonist CCX832 at Chemerin Receptors
CMKLR1 and GPR1
To characterize the binding and activation of CMKLR1 and
GPR1, the human receptors were individually expressed in
CHO-K1 cells. Radiolabeled C9 bound to CMKLR1 and GPR1
with a similar subnanomolar afﬁnity (KD=0.280.07 and
0.870.23 nmol/L, respectively).
Activities of full-length chemerin and C9 were compared in
downstream signaling assays. The C-terminal fragment C13
was included to further investigate a trend of biased signaling.
In cell-based functional assays with CMKLR1, chemerin, C9,
and C13 exhibited comparable maximum responses (Table 1).
C-terminal fragments, C9 and C13 (pD2=9.390.09 and
Figure 5. C9 is active in vivo in rats. A, Example trace of initial DRC to C9 carried out to determine EC70
value of 200 nmol. B, C9 (200 nmol, blue) caused a signiﬁcant (Student t test; ****P<0.0001; n=12 rats)
increase in mean arterial blood pressure (MAP) in vivo in normotensive rats. C, Repeated doses of C9
(200 nmol) caused similar increases in blood pressure (n=6 rats). D, CCX832 alone (40 nmol, black) had no
further effect on BP than saline control (white); however, when infused with C9 (pink), there was a
signiﬁcant (Student t test; ***P<0.001; n=6 rats) reduction in pressor response. Responses are shown as
absolute values (A and B) or expressed as % of ﬁrst C9 dose (C and D). E, Effect of C9 (200 nmol, blue) on
heart rate (HR) in vivo compared to saline controls (open bars). F, Effect of CCX832 alone (40 nmol, black)
and C9 in the presence of CCX832 (pink) on HR. Data are expressed as the % difference in HR of peak
response compared to baseline, meanSEM. BP indicates blood pressure; DRC, dose-response curve; EC70,
70% effective concentration.
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9.120.12, respectively) were more potent than chemerin
(pD2=8.450.10) at inhibiting forskolin-evoked cAMP accu-
mulation (Figure 7A). However, compared to chemerin
(pD2=9.370.05), C9 and C13 were less potent
(pD2=7.090.06, and 7.150.04, respectively) at recruiting
b-arrestin (Figure 7B). Using chemerin as the reference
endogenous ligand, bias analysis conﬁrmed that the
C-terminal fragments had a bias factor of 3000 to 5000
for inhibition of cAMP accumulation compared to b-arrestin
recruitment (Table 2).
Chemerin was functionally active at the GPR1 receptor in
b-arrestin recruitment assays (pD2=9.050.09; Figure 7C).
C9 and C13 (pD2=8.090.16 and 8.650.14, respectively)
were less potent at recruiting b-arrestin and appear to be
partial agonists (Emax=715% and 973%, respectively)
compared to chemerin (Emax=1346%).
To conﬁrm the selectivity of reported CMKLR1 antagonist,
binding and functional studies were carried out using the
same cell lines. CCX832 competed for radiolabeled C9
binding to CMKLR1 (pKi=9.160.42; Figure 8A), but not
GPR1 (Figure 8B). It blocked the C9-mediated b-arrestin
recruitment at CMKLR1 (pA2=8.320.04, Figure 8C), but had
no effect on the C9 response at GPR1 (Figure 8D).
Discussion
This is the ﬁrst study to investigate fully the role of chemerin
on human vascular contractility. We have identiﬁed that a
single receptor, CMKLR1, mediates the vasoconstrictor
actions of C9 in humans and, importantly, conﬁrmed that
the actions of C9 and CMKLR1 selective antagonist, CCX832,
translate into the rat in vivo, identifying a robust animal model
required for preclinical drug development studies.
Chemerin and Chemerin Receptors Are Widely
Expressed in the Human Vasculature
Localization of GPR1 has not been investigated in the human
cardiovascular system before, and expression of chemerin and
CMKLR1 has only been identiﬁed in atherosclerotic coronary
arteries and aorta33 and isolated mesenteric arteries.19 Before
all else, it was therefore imperative to deﬁnitively locate the 3
potential components of the chemerin axis in healthy human
cardiovascular tissues to begin to understand their function.
Our results show that mRNA and protein of both chemerin
receptors, CMKLR1 and GPR1, are widely expressed in
smooth muscle, the contractile element, of large conduit
vessels and small internal vessels within organs in the human
cardiovascular system, suggesting that they could have an
important role in modulation of vascular tone. This is
consistent with previous ﬁndings of CMKLR1 expression on
smooth muscle in human33 and rat19 vessels. There was
relatively more CMKLR1 mRNA than GPR1 mRNA in all human
vessels tested, although GPR1 mRNA was more abundant
than CMKLR1 mRNA in human ASMCs. The difference may be
a consequence of culturing ASMCs or reﬂect that homo-
genates contained smooth muscle, endothelial cells, and
adventitia. CMKLR1 was previously reported to be expressed
on cultured endothelial cells,6 and GPR1 has not.
Chemerin mRNA and protein localized to the endothelium,
smooth muscle, and fat cells of human vessels, placing it in
close proximity to its receptors, suggesting that it could act as
a locally released mediator and levels could be elevated in
pathologies, such as obesity and metabolic syndrome. This
staining is consistent with other literature, which found that
Figure 6. Inhibition of cAMP accumulation by C9
through CMKLR1. A, In human ASMCs stimulated
with NKH477 (3 lmol/L), C9 (1 lmol/L) signiﬁ-
cantly (Student t test; *P<0.05; n=3 patient cell
lines) inhibited cAMP accumulation. Pretreatment
with CCX832 (100 nmol/L) blocked this response.
Responses are expressed as meanSEM. (B) In rat
aorta primed to produce cAMP (see trace), C9
induced greater contractions (▼), compared to a
C9 control response from baseline (▼). Responses
are shown as % of contraction evoked by
100 mmol/L of KCl and expressed as meanSEM
(n=4 rats). ASMCs indicates aortic smooth muscle
cells; CMKLR1, chemokine-like receptor 1.
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chemerin was expressed in dermal microvascular endothelial
cells34 and the smooth muscle medial layer of arteries.33
Interestingly, expression in smooth muscle is similar to
another adipokine, adiponetin.35 Chemerin is released as
biologically inactive prochemerin and must be cleaved at the
C-terminus for activation, by enzymes present in the vascu-
lature.36–38 Our chemerin antibody was designed to detect
expression of all chemerin isoforms, and so the identity of
active chemerin proteins or peptides within the human vessel
wall has not yet been determined.
CCX832 Is a Highly Selective Antagonist for
CMKLR1
Chemerin is proposed to act through 2 GPCRs.9,10,13 Our
results are in agreement with 2 previous studies: Chemerin
activates both CMKLR1 and GPR1 with a similar potency in
b-arrestin recruitment assays.16 At both receptors, radiola-
beled C9 bound with a similar subnanomolar afﬁnity,13 and
the C-terminal fragments stimulated b-arrestin recruitment.
This conﬁrms the pairing of GPR1 with the ligand chemerin
and shows that both CMKLR1 and GPR1 are activated by
C9.
Given that there are two chemerin receptors, and both are
present in human vessels, it is crucial to determine whether 1
or both receptors mediate the effect of chemerin, if these
ﬁndings are going to translate into a clinical setting. CCX832
is a small-molecule compound, previously only characterized
by high-throughput screen.19 Since then, GPR1 has been
identiﬁed as a chemerin receptor because of its high
sequence identity with CMKLR1,13 and our data conﬁrm this
pairing. We present the full characterization of CCX832,
Table 1. Pharmacological Data for Chemerin Peptides at CMKLR1 and GPR1 as Observed in Radioligand Binding and Functional
Assays (Figure 7)
CMKLR1 GPR1
Ligand binding [125I]-C9 KD=0.280.07 nmol/L (n=3) KD=0.870.23 nmol/L (n=3)
Competition
binding
C9 pKi=9.210.14 (n=3) pKi=8.810.17 (n=3)
CCX832 pKi=9.160.42 (n=6) No effect (n=3)
pD2 Emax (%) n pD2 Emax (%) n
b-Arrestin
recruitment
Chemerin 9.370.05 1136 3 9.050.09 1346 3
C9 7.090.06 964 3 8.090.16 715 7
C13 7.150.04 942 6 8.650.14 973 9
cAMP
inhibition
Chemerin 8.450.10 4.33.7 3 —
C9 9.390.09 0.90.4 4 —
C13 9.120.12 5.71.5 3 —
CMKLR1 indicates chemokine-like receptor 1; GPR1, G-protein-coupled receptor 1.
Figure 7. Functional activity of (●) chemerin, (▼) C9 and (♦) C13 at heterologously expressed CMKLR1
and GPR1. Potencies of peptides were determined from measurements of inhibition of cAMP accumulation
through CMKLR1 (A) and b-arrestin recruitment through CMKLR1 (B) and GPR1 (C). Responses are shown
as % of the maximal response to C13 and show meanSEM (n=3–9 independent replicates). Calculated
functional parameters are presented in Table 1. CMKLR1 indicates chemokine-like receptor 1; GPR1, G-
protein-coupled receptor 1.
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through binding and functional studies, to conﬁrm that it is
selective for CMKLR1 and has no effect at GPR1.
Novel Role of CMKLR1 in Blood Pressure
Regulation
We present, for the ﬁrst time, compelling evidence that
CMKLR1 mediates the vascular actions of chemerin in human.
Our data show that C9 caused a concentration-dependent
contraction of human SV, which was blocked by CCX832,
consistent with the radiolabeled binding data that C9 binds
and functions through CMKLR1. This effect of C9 was not
limited to the venous system, but, importantly, it was also
observed in the more physiologically relevant human resis-
tance arteries, which directly contribute to blood pressure. In
human ASMCs, C9 inhibited cAMP accumulation through
CMKLR1. CMKLR1 is known to activate the Gi class of G
proteins,9 suggesting that C9 is probably activating Gi, and
Table 2. C-Terminal Fragments Display Bias Towards Gi Pathway over b-Arrestin Recruitment, Compared to Chemerin at CMKLR1
b-Arrestin Assay cAMP Assay cAMP vs b-Arrestin
logR* DlogR RE† logR* DlogR RE† DDlogR Bias Factor
Chemerin 9.580.04 0.000.06 1 8.380.04 0.000.06 1 0.000.09 1
C13 7.200.03 2.370.04 0.004 9.510.14 1.140.20 13.8 3.520.21 3278.44
C9 6.740.04 2.830.05 0.001 9.270.06 0.890.08 7.73 3.720.10 5280.40
CMKLR1 indicates chemokine-like receptor 1.
*logR=log10(Ƭ/KA) where Ƭ is a measure of agonist efﬁcacy and KA is the agonist functional afﬁnity.
†RE is the relative effectiveness compared to chemerin.
Figure 8. Characterization of small-molecule CCX832 using cells expressing CMKLR1 or GPR1.
Radiolabeled competition binding studies, with CCX832 (■) and unlabeled C9 (▼) as the competing
ligands, revealed that CCX832 competed for all binding of radiolabeled C9 to CMKLR1 (A), but had no
effect on binding to GPR1 (B). Data are expressed as a % of the total speciﬁc binding and show meanSEM
(n=3–6 independent replicates). pKi values are shown in Table 1. In b-arrestin recruitment assays,
increasing concentrations of CCX832 caused a rightward shift of C9 response at CMKLR1 (C)
(pA2=8.320.04), but had no effect at GPR1 (D). Data are expressed as % of the maximum response to
C13 in each assay and show meanSEM (n=3 independent replicates). CMKLR1 indicates chemokine-like
receptor 1; GPR1, G-protein-coupled receptor 1.
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thereby inhibits adenylyl cyclase. This mechanistic study is
the ﬁrst to identify the signaling pathway linking C9 with
contraction and is consistent with other Gi-coupled vasocon-
strictors acting on, for example, a2-adrenoceptors in the
peripheral circulation39 or M2 muscarinic receptors on
smooth muscle.40
C9-evoked contraction translated into an increase in MAP
in rats in vivo, which was attenuated by CCX832. This
conﬁrms that CMKLR1 has a role in blood pressure regulation,
matching its expression in the medial layer of rat vessels.19
CCX832 did not completely abrogate the pressor response to
C9, and this is thought to be because it is a competitive
antagonist and therefore its effects are expected to be
surmountable. It is likely that CCX832 was not at a high
enough concentration to completely block the increase in
blood pressure, and because of the compound’s solubility, it
was not possible to increase the concentration further.
Experiments in vitro suggest that inhibition of cAMP accu-
mulation contributes to the contraction evoked by C9 in rat
aorta, consistent with our results in human cells. Our in vitro
and in vivo studies in rats have therefore identiﬁed a robust
animal model for further studies into the vasculature actions
of chemerin and CMKLR1. Importantly, these direct actions of
chemerin are in agreement with previous in vitro studies in rat
aorta.19 Indirect actions have also been reported in rat aorta,
where chemerin modulates the actions of other vasoactive
mediators.41,42 A previous study by Kunimoto et al20 identi-
ﬁed that chronic infusion of chemerin caused an increase in
systolic blood pressure in mouse in vivo, but they did not
identify the mechanism. Watts et al19 reported that chemerin
had no constrictor action in mouse aorta, even though
CMKLR1 is present, and this discrepancy suggests that the
mouse is an unreliable model and requires further study into
how chemerin modulates blood pressure in mice.
Biased Agonism at CMKLR1
Biased agonism is emerging as an important concept in GPCR
research and has the potential to revolutionize how novel
drugs for cardiovascular disease treatment are made.43,44 In
this study, we used chemerin(21–157) as our reference
compound because it is found in human ascitic ﬂuid9 and is
reported to be the most active endogenous isoform of
chemerin.1 We have identiﬁed that C-terminal fragment, C9,
previously reported to mimic the actions of chemerin,18 has a
similar potency to chemerin in cAMP inhibition assays only,
but is signiﬁcantly less potent at activating b-arrestin. We saw
a similar phenomenon with C-terminal fragment C13, sug-
gesting a trend for shorter C-terminal fragments of chemerin
to be strongly biased toward activation of Gi protein pathway
over the b-arrestin pathway at the CMKLR1 receptor. This
suggests that endogenous chemerin fragments have the
Figure 9. Chemerin is a multifaceted protein that is emerging as a potential contributor to cardiovascular
disease. This study identiﬁes a novel role of chemerin in modulation of vascular tone in humans. CMKLR1
indicates chemokine-like receptor 1; SMC, smooth muscle cells.
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potential to exhibit a spectrum of activities at different
signaling pathways. Given that there are reported to be many
cleavage sites within the protein36,45 and it is not yet known
what the active form of chemerin is in the vasculature, this
could be important, and others in the ﬁeld have already noted
potential at CMKLR1.46 Chemerin has a reverse chemokine
conformation18 and chemokines bind to their receptors in a 2-
site model, where the C-terminal core of the chemokine is
necessary for binding and the ﬂexible N-terminus for activa-
tion.47 This therefore suggests that chemerin could activate
its receptor in a similar way, with the N-terminus and C-
terminus being able to stabilize different conformations of the
receptor and therefore activate different signaling pathways.
Chemerin/CMKLR1 Contribution to
Cardiovascular Disease?
Activation of CMKLR1 by chemerin has well-established roles
in inﬂammation, adipogenesis, and insulin sensitivity, and thus
chemerin has a ﬁrm role in the pathology of obesity and
metabolic syndrome.1 There is increasing recognition of the
association between metabolic syndrome and cardiovascular
disease. High blood pressure could be a potential link given
that it contributes both to metabolic syndrome and is a major
risk factor for cardiovascular disease. Circulating chemerin
concentration positively correlates with both systolic and
diastolic blood pressure in a range of patient populations,
particularly those with obesity,48 metabolic syndrome,49–52
type 2 diabetes mellitus,53,54 and type 2 diabetes mellitus
with hypertension,7 and these patient groups are at higher
risk of developing cardiovascular disease. Our data show, for
the ﬁrst time, that chemerin causes concentration-dependent
contraction of human blood vessels and has a direct effect on
blood pressure in rats by binding to CMKLR1 on the smooth
muscle layer. This allows us to propose a novel mechanism by
which chemerin contributes to both cardiovascular disease
and metabolic syndrome in addition to its well-established
roles (Figure 9).
Conclusions
We provide evidence that the G-protein-coupled receptor,
CMKLR1 which is activated by chemerin, is a tractable drug
target. This study identiﬁes a novel role of CMKLR1 in
contraction of human resistance arteries. The C-terminal
nonapeptide, C9, has been identiﬁed as a potent agonist, and
CCX832 is shown to be a highly selective antagonist of
CMKLR1, both of which are effective in vitro and in vivo in rat
models. Importantly, our study has conclusively identiﬁed that
CCX832 blocks the constrictor effects of chemerin, providing
a proof of principle that targeting the chemerin/CMKLR1 axis
could deliver a novel therapeutic opportunity in the treatment
of hypertension.
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